Day 1

Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure Treatment

solaci
solaci
415
0

Editorial Comment: Fifty per cent of all HF patients involves Diastolic Heart Failure or HF with conserved ventricular function. This study aimed at evaluating the efficacy and safety of 25mg spironolactone after a year of therapy. Results showed improved diastolic function, induced structural inverse remodelling, reduced neuroendocrine activation and reduced blood pressure (effects on cardiac structure and function remained significant after adjusting for blood pressure changes). Authors concluded that, in addition to safety, this drug is an effective alternative to treat these patients

aldoHF-slides
B. Pieske
2012-08-25

Original title: Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure

Previous article
PARAMOUNT: Promising results of double action drug treatment for patients with heart failure and preserved ejection fraction .
Next article
DeFACTO: Diagnostic Precision of CT Angiography in Determining FFR.
solaci
solaci

More articles by this author

TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization.

solaci - 0
 TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization. Read articleMagnus Ohman2012-08-25

DeFACTO: Diagnostic Precision of CT Angiography in Determining FFR.

solaci - 0
 DeFACTO: Diagnostic Precision of CT Angiography in Determining FFR.  Read articleJames K. Min2012-08-25

PARAMOUNT: Promising results of double action drug treatment for patients with heart failure and preserved ejection fraction .

solaci - 0
Editorial Comment: This Phase II study included 149 patients following these criteria: NYHA II-IV heart failure, +40 yr, LVEF ≥ 45% NT-proBNP> 400 pg/ml....

ALTITUDE: Aliskiren Trial In Type 2 Diabetes Using Cardio Renal Endpoints.

solaci - 0
Editorial Comment: Morbimortality in diabetic patients is still a matter of deep concern in the context of reduced cardiovascular mortality of recent years. Based...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 1

TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization.

 TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization. Read articleMagnus Ohman2012-08-25
solaci -
SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Dr. Juan Manuel Pérez - 0
Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Dr. Juan Manuel Pérez - 0
Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Dr. Juan Manuel Pérez - 0
Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...